"NICE recommends olaparib (also known as Lynparza, and manufactured by AstraZeneca) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer. The drug is for cancers in adults who have tested positive for the BRCA1 or BRCA2 mutations, and whose disease has responded to platinum-based chemotherapy.
Specifically, the recommendations say that olaparib should be available for people only if they have had 3 or more courses of platinum-based chemotherapy and the drug cost of olaparib for people who remain on treatment after 15 months is met by the company."
The ERG included HEDS’ own Paul Tappenden, Sue Harnan, Shijie Ren, Praveen Thokala, Ruth Wong and Clara Mukuria.